APR 11, 2018 09:00 AM PDT

Conversion of Group A Streptococcus Confirmation Testing from Culture to Molecular: Automation, Workflow Improvements and Antimicrobial Stewardship

SPONSORED BY: Diasorin, Inc.
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • System Director, Clinical and Molecular Biology at Geisinger Diagnostic Medicine Institute
    Biography
      Dr. Donna Wolk is the System Director for Clinical and Molecular Microbiology at Geisinger Health System, an integrated delivery system in Pennsylvania. As a Diplomate of the American Board of Medical Microbiology (ABMM), Dr. Wolk's professional practice extends to the national and international level, supporting initiatives in clinical and molecular microbiology and laboratory leadership. Active in the American Society of Microbiology, among others, she is most well known for her strategic thinking and predications about new technology and its impact to patient care, as well as her work as one of seven founding members of CDC/ASM collaboration for Evidence Based Laboratory Medicine Best Practices. Dr. Wolk was selected as a Clinical Research Scholar at the University of Arizona and in 2012, she received the 1885 Distinguished Scholar Award, which acknowledges outstanding faculty whose research, scholarship, and creative contributions exemplify innovation, service, and success in their respective disciplines. She is the 2016 award laureate, selected by the American Society for Microbiology to receive the BD Award for Clinical Research in Microbiology.

    Abstract:

    Streptococcus pyogenes or Group A Streptococcus (GAS) is a pathogenic bacteria that causes both invasive and non-invasive infections resulting in mild to severe life-threatening disease.

    Laboratory guidelines mandate that a more sensitive confirmatory test is performed on negative rapid antigen samples. However, routine culture detection of the organism can take an additional 24-48 hours. As an alternative, rapid molecular testing for Group A Strep can offer a faster and more efficient method for confirmation, contributing to the accelerated treatment of the patient.

    During this presentation you will learn how our laboratory implemented a rapid, automated highthroughput method for molecular confirmation of rapid antigen negatives. The advantages of moving this assay from culture to molecular in terms of workflow and increased sensitivity will be discussed.


    Show Resources
    You May Also Like
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    SEP 12, 2017 08:00 AM PDT
    SEP 12, 2017 08:00 AM PDT
    DATE: September 12, 2017TIME: 8:00am PT, 11:00am ETEvery year, millions of dollars are wasted on poorly characterized and performing antibodies.  Key researchers in the antibody co...
    APR 25, 2018 07:00 AM PDT
    C.E. CREDITS
    APR 25, 2018 07:00 AM PDT
    DATE: April 25, 2018TIME: 1500 CET, 10:00 a.m. EST, 7:00 a.m. PST Hematology and coagulation laboratories perform a wide range of routine and specialized tests, allowing clinicians to...
    Loading Comments...